These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


188 related items for PubMed ID: 15553220

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Enthalpy relaxation studies of two structurally related amorphous drugs and their binary dispersions.
    Bansal SS, Kaushal AM, Bansal AK.
    Drug Dev Ind Pharm; 2010 Nov; 36(11):1271-80. PubMed ID: 20815794
    [Abstract] [Full Text] [Related]

  • 23. Stability study of amorphous valdecoxib.
    Ambike AA, Mahadik KR, Paradkar A.
    Int J Pharm; 2004 Sep 10; 282(1-2):151-62. PubMed ID: 15336390
    [Abstract] [Full Text] [Related]

  • 24. Study on mechanism for amorphous drug stabilization using gelucire 50/13.
    Shimpi SL, Mahadik KR, Paradkar AR.
    Chem Pharm Bull (Tokyo); 2009 Sep 10; 57(9):937-42. PubMed ID: 19721253
    [Abstract] [Full Text] [Related]

  • 25. Use of surfactants as plasticizers in preparing solid dispersions of poorly soluble API: stability testing of selected solid dispersions.
    Ghebremeskel AN, Vemavarapu C, Lodaya M.
    Pharm Res; 2006 Aug 10; 23(8):1928-36. PubMed ID: 16871443
    [Abstract] [Full Text] [Related]

  • 26. Poly(2-Ethyl-2-Oxazoline) as an Alternative to Poly(Vinylpyrrolidone) in Solid Dispersions for Solubility and Dissolution Rate Enhancement of Drugs.
    Fael H, Ràfols C, Demirel AL.
    J Pharm Sci; 2018 Sep 10; 107(9):2428-2438. PubMed ID: 29859957
    [Abstract] [Full Text] [Related]

  • 27. Amorphous Salts Solid Dispersions of Celecoxib: Enhanced Biopharmaceutical Performance and Physical Stability.
    Mukesh S, Joshi P, Bansal AK, Kashyap MC, Mandal SK, Sathe V, Sangamwar AT.
    Mol Pharm; 2021 Jun 07; 18(6):2334-2348. PubMed ID: 34003656
    [Abstract] [Full Text] [Related]

  • 28. Experimental, Thermodynamic, and Molecular Modeling Evaluation of Amorphous Simvastatin-Poly(vinylpyrrolidone) Solid Dispersions.
    Kapourani A, Chatzitheodoridou M, Kontogiannopoulos KN, Barmpalexis P.
    Mol Pharm; 2020 Jul 06; 17(7):2703-2720. PubMed ID: 32520564
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Solubility advantage from amorphous etoricoxib solid dispersions.
    Dani P, Puri V, Bansal AK.
    Drug Dev Ind Pharm; 2014 Jan 06; 40(1):92-101. PubMed ID: 23301771
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Inhibition of albendazole crystallization in poly(vinylpyrrolidone) solid molecular dispersions.
    Kalaiselvan R, Mohanta GP, Manna PK, Manavalan R.
    Pharmazie; 2006 Jul 06; 61(7):618-24. PubMed ID: 16889070
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Influence of PVP/VA copolymer composition on drug-polymer solubility.
    Rask MB, Knopp MM, Olesen NE, Holm R, Rades T.
    Eur J Pharm Sci; 2016 Mar 31; 85():10-7. PubMed ID: 26826280
    [Abstract] [Full Text] [Related]

  • 38. Comparing various techniques to produce micro/nanoparticles for enhancing the dissolution of celecoxib containing PVP.
    Homayouni A, Sadeghi F, Varshosaz J, Garekani HA, Nokhodchi A.
    Eur J Pharm Biopharm; 2014 Sep 31; 88(1):261-74. PubMed ID: 24952357
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Design and evaluation of celecoxib porous particles using melt sonocrystallization.
    Paradkar A, Maheshwari M, Kamble R, Grimsey I, York P.
    Pharm Res; 2006 Jun 31; 23(6):1395-400. PubMed ID: 16741659
    [Abstract] [Full Text] [Related]


    Page: [Previous] [Next] [New Search]
    of 10.